# Cannabis Science Evidence Report: Systematic Review and Meta-Analysis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/prevalence-cannabis-use-disorder-early-onset-psychosis/ > **Published:** 2026-07-01T10:16:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:50:09-04:00 > **Clinical Summary:** Explore the prevalence cannabis use disorder early-onset psychosis through a systematic review and meta-analysis revealing key clinical insights. --- CED Clinical Relevance #100 Strong Clinical Relevance This Clinical Evidence Update appears relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), but clinical translation depends on source verification and limitations. Clinical Insight | CED Clinic To quantify the prevalence of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) (CU) and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorders (CUD) in Early-Onset Psychosis (EOP; <18 years) and examine their correlates, clinical and functional impact. This PRISMA-compliant systematic review and meta-analysis (CRD420251070701) searched six databases until 1/7/2025, for studies evaluating CU/CUD in EOP. Data were extracted by independent researchers, and quality assessment was conducted using the Newcastle-Ottawa Scale. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A narrative synthesis was conducted. Forty studies (N=3,473; age=16.2±1.6 years; male=59%) were included. In EOP, pooled prevalence was for current CU 32.8… The source should be read as educational context, not individualized medical advice, and the strength of inference depends on the study design. This home-LLM draft preserves the existing CED Clinic caution standard by separating what the source appears to report from what it can prove clinically. It also keeps missing source details visible, so a reader understands when the correct next step is verification rather than stronger interpretation. Clinical Evidence Update[Cannabis Medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/)Journal ArticleClinical CautionCED Clinic Audience Patients, clinicians, caregivers, and cannabis-medicine readers Primary Topic Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in Early-Onset Psychosis. Source [Read the full study](https://pubmed.ncbi.nlm.nih.gov/42331312/) To quantify the prevalence of cannabis use (CU) and cannabis use disorders (CUD) in Early-Onset Psychosis (EOP; <18 years) and examine their correlates, clinical and functional impact. This PRISMA-compliant systematic review and meta-analysis (CRD420251070701) searched six databases until 1/7/2025, for studies evaluating CU/CUD in EOP. Data were extracted by independent researchers, and quality assessment was conducted using the Newcastle-Ottawa Scale. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A narrative synthesis was conducted. Forty studies (N=3,473; age=16.2±1.6 years; male=59%) were included. In EOP, pooled prevalence was for current CU 32.8… The practical question is not whether this source is interesting, but how much clinical weight it can safely carry. What This Study Teaches Us This source teaches that cannabis evidence often arrives with a useful signal and a boundary around interpretation. The source should be read as educational context, not individualized medical advice, and the strength of inference depends on the study design. Why This Matters Patients and clinicians need help translating [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) without turning early or incomplete evidence into advice. This item matters because it can sharpen a clinical conversation while still requiring careful attention to study design, population, comparator, and outcome measurement. Study Snapshot Evidence Lane Clinical Evidence Update Study Type Journal Article Population Verify from primary source Exposure or Intervention Verify from primary source Comparator Verify from primary source Primary Outcomes Verify from primary source Journal or Source Journal of the American Academy of Child and Adolescent Psychiatry Published 2026Jun22 PMID 42331312 DOI 10.1016/j.jaac.2026.06.012 Important Limitation The discovery record alone is not enough to make strong clinical claims. Clinical Bottom Line This item can support a careful educational conversation, but it should not be converted into product advice, dosing advice, or a promise of benefit. What the Source Appears to Report To quantify the prevalence of cannabis use (CU) and cannabis use disorders (CUD) in Early-Onset Psychosis (EOP; <18 years) and examine their correlates, clinical and functional impact. This PRISMA-compliant systematic review and meta-analysis (CRD420251070701) searched six databases until 1/7/2025, for studies evaluating CU/CUD in EOP. Data were extracted by independent researchers, and quality assessment was conducted using the Newcastle-Ottawa Scale. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A narrative synthesis was conducted. Forty studies (N=3,473; age=16.2±1.6 years; male=59%) were included. In EOP, pooled prevalence was for current CU 32.8… The first clinical task is to identify what was actually measured, who was included, and whether the source can support the claim readers may want to draw from it. Why the Signal Is Clinically Interesting [Cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) needs evidence that connects mechanisms and real patient outcomes without blurring the difference between possibility and proof. This item appears relevant because it touches a question patients or clinicians may reasonably ask in practice. Where Interpretation Needs Restraint The safest reading keeps the evidence lane visible. Preclinical, observational, protocol, review, and randomized evidence do not answer the same clinical question. Any missing information about comparator, population, dose, route, outcome ascertainment, funding, or adverse events should lower confidence until verified. How to Translate This Safely The responsible translation is to use the source as context for better questions, not as a substitute for individualized clinical care. A clinician-facing reading should preserve uncertainty, avoid causal overreach, and name the next evidence step that would make the signal more useful. How Strong Is This Evidence? The evidence strength depends on the primary source design, population, comparator, and outcome measurement. The home pipeline therefore treats the discovery record as a starting point and keeps source verification visible. Where This Paper Deserves Skepticism The strongest skepticism concerns overtranslation. Cannabis findings can be clinically meaningful while still being too preliminary, too indirect, or too confounded to guide a specific patient decision without more context. What This Paper Does Not Show This source does not show that cannabis is appropriate for every patient, that a specific product or dose is best, or that benefits outweigh risks in a different clinical setting. How This Fits With the Broader Clinical Conversation Cannabis medicine sits at the intersection of patient experience, mechanistic plausibility, [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), observational research, and public health caution. The most useful CED Clinic interpretation keeps those evidence layers separate while helping readers understand why the source is worth attention. That balance is the point of the home LLM workflow: local models can draft and structure, while validation gates protect the clinical boundary. Dr. Caplan’s Take *I would read this as a signal that deserves careful attention, not as a shortcut to a clinical conclusion.* *The useful question is what this source helps us ask more precisely, and where the evidence still needs a stronger design before it changes care.* What a Careful Reader Should Take Away A careful reader should leave with both curiosity and restraint: the item may be relevant to cannabis medicine, but the source details determine how much clinical weight it deserves. Evidence Interpretation Guide Table of Contents - [How to Read This Cannabis Evidence Without Overstating It](#How_to_Read_This_Cannabis_Evidence_Without_Overstating_It)[A Better Reading Order](#A_Better_Reading_Order) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[What Patients Can Safely Take From This](#What_Patients_Can_Safely_Take_From_This) - [How a Clinician Might Use This](#How_a_Clinician_Might_Use_This) - [Where the Evidence Can Be Overread](#Where_the_Evidence_Can_Be_Overread) - [What the Design Still Needs](#What_the_Design_Still_Needs) - [How It Fits the Broader Evidence](#How_It_Fits_the_Broader_Evidence) - [What Would Need Monitoring](#What_Would_Need_Monitoring) - [What Better Evidence Should Test](#What_Better_Evidence_Should_Test) - [What Not to Claim](#What_Not_to_Claim) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read This Cannabis Evidence Without Overstating It The safest reading starts by separating what the source reports from what it proves. That discipline is especially important in cannabis medicine, where public enthusiasm can outrun the evidence. ### A Better Reading Order **Start with the study design**Identify whether this is randomized, observational, preclinical, a protocol, a review, or a policy source. **Find the comparator**Ask what the cannabis exposure was compared against, because comparator choice determines the strength of interpretation. **Check patient relevance**Look for population, dose, route, outcomes, adverse events, and follow-up before translating the finding. **Separate signal from advice**A signal can justify better questions without becoming a recommendation for an individual patient. The Main Research Question What does this source add to the cannabis medicine conversation about Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis? The Practical Patient Question Should this finding change what I ask my clinician, and what should I still avoid assuming? The Bottom Line Useful evidence improves the conversation before it changes the recommendation. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated. Overview The same cannabis source can look promising, limited, practical, or risky depending on the question being asked first. #### What Patients Can Safely Take From This This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### How a Clinician Might Use This This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### Where the Evidence Can Be Overread This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### What the Design Still Needs This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### How It Fits the Broader Evidence This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### What Would Need Monitoring This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### What Better Evidence Should Test This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. #### What Not to Claim This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion. The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible. Lens takeaway The evidence can inform better questions without becoming individualized advice. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+Science+Evidence+Report%3A+Systematic+Review+and+Meta-Analysis%3A+Prevalence%2C+Correlates%2C+and+Impact+of+Cannabis+Use+and+Cannabis+Use+Disorder+i&url=https%3A%2F%2Fcedclinic.com%2Fsystematic-review-and-meta-analysis-prevalence-correlates-and-impact-of%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fsystematic-review-and-meta-analysis-prevalence-correlates-and-impact-of%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+Science+Evidence+Report%3A+Systematic+Review+and+Meta-Analysis%3A+Prevalence%2C+Correlates%2C+and+Impact+of+Cannabis+Use+and+Cannabis+Use+Disorder+i%20https%3A%2F%2Fcedclinic.com%2Fsystematic-review-and-meta-analysis-prevalence-correlates-and-impact-of%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis Use Disorder in Early-Onset Psychosis.](https://pubmed.ncbi.nlm.nih.gov/42331312/) Related Reading at CED Clinic Continue exploring the evidence [High-Dose CBD Significantly Reduced Neuropathic Pain in Spinal Cord Injury: What a New RCT Reveals](https://cedclinic.com/high-dose-cbd-neuropathic-pain-spinal-cord-injury/) A controlled pain-study reference point for comparing newer cannabis pain findings. [Read the RCT](https://cedclinic.com/high-dose-cbd-neuropathic-pain-spinal-cord-injury/) [Endocannabinoid System and Opioids: What a New Review Says About Pain and OUD](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) CED context on cannabinoid-pathway pain discussions and opioid-related clinical questions. [Review the context](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) [Cannabinoids for Cancer Pain: New Review Questions the Opioid-Sparing Claim](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) A useful cautionary comparison for opioid-sparing and pain-relief claims. [Compare the caution](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) ## Frequently Asked Questions Does this source prove cannabis works for this condition? Not by itself. The strength of the claim depends on the primary source design, comparator, population, and outcomes. Can patients use this as medical advice? No. This is educational interpretation and should not replace individualized clinical care. Why does study design matter so much? Design determines whether a source can support causation, association, mechanism, or only a hypothesis. What should clinicians look for first? Clinicians should start with population, intervention or exposure, comparator, outcomes, adverse events, and follow-up. What if the finding is preclinical? Preclinical findings may explain mechanisms, but they should not be treated as proof of patient benefit. What if the finding is observational? Observational findings can be clinically useful, but confounding and selection effects must stay visible. How should safety be interpreted? Safety needs route, dose, population, duration, and adverse-event capture before it can be generalized. Does this identify the best product or dose? No. A source usually cannot identify an optimal product or dose unless it directly tested that question. Why include related CED Clinic reading? Related reading helps readers compare this source with earlier coverage and avoid interpreting one item in isolation. What is the main takeaway? The main takeaway is to read Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Canna with curiosity and restraint. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).